Kane Biotech Inc KNBIF

Primary Symbol: V.KNE

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc > New Corporate Presentation

<< Previous

Bullboard Posts

Next >>

Comment by KevinOlearyon Sep 20, 2024 6:57pm

69 Views

Post# 36234172

RE:RE:RE:RE:RE:RE:RE:New Corporate Presentation

The exchange limits how much forward guidance you can provide without revenues. You think exactly $3M per product, per year is a scientific calculation? Wait for a few quarters to see how Revyve and the mystery acquisition does instead of impatiently demanding info that can't be provided, then pretending $3M is useful.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"